|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.24 USD | -0.90% |
|
+15.81% | +19.13% |
| Apr. 26 | North American Morning Briefing : Tech Still in -2- | DJ |
| Apr. 25 | Leerink Partners Upgrades Tandem Diabetes Care to Outperform Rating, Price Target is $45 | MT |
Tandem Diabetes Care, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 747.72 million compared to USD 801.22 million a year ago. Net loss was USD 222.61 million compared to USD 94.59 million a year ago.
Basic loss per share from continuing operations was USD 3.43 compared to USD 1.47 a year ago. Diluted loss per share from continuing operations was USD 3.43 compared to USD 1.47 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +19.13% | 2.28B | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.36% | 26.25B | |
| +2.07% | 26.48B | |
| +12.96% | 24.62B |
TANDEM DIABETES CARE, INC. 
